198 related articles for article (PubMed ID: 15496535)
1. CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.
Keshava C; McCanlies EC; Weston A
Am J Epidemiol; 2004 Nov; 160(9):825-41. PubMed ID: 15496535
[TBL] [Abstract][Full Text] [Related]
2. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients.
Paris PL; Kupelian PA; Hall JM; Williams TL; Levin H; Klein EA; Casey G; Witte JS
Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):901-5. PubMed ID: 10548319
[TBL] [Abstract][Full Text] [Related]
3. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men.
Bangsi D; Zhou J; Sun Y; Patel NP; Darga LL; Heilbrun LK; Powell IJ; Severson RK; Everson RB
Urol Oncol; 2006; 24(1):21-7. PubMed ID: 16414488
[TBL] [Abstract][Full Text] [Related]
4. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer.
Spurdle AB; Goodwin B; Hodgson E; Hopper JL; Chen X; Purdie DM; McCredie MR; Giles GG; Chenevix-Trench G; Liddle C
Pharmacogenetics; 2002 Jul; 12(5):355-66. PubMed ID: 12142725
[TBL] [Abstract][Full Text] [Related]
5. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4.
Zeigler-Johnson CM; Walker AH; Mancke B; Spangler E; Jalloh M; McBride S; Deitz A; Malkowicz SB; Ofori-Adjei D; Gueye SM; Rebbeck TR
Hum Hered; 2002; 54(1):13-21. PubMed ID: 12446983
[TBL] [Abstract][Full Text] [Related]
6. The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer.
Kadlubar FF; Berkowitz GS; Delongchamp RR; Wang C; Green BL; Tang G; Lamba J; Schuetz E; Wolff MS
Cancer Epidemiol Biomarkers Prev; 2003 Apr; 12(4):327-31. PubMed ID: 12692107
[TBL] [Abstract][Full Text] [Related]
7. Studies on CYP1A1, CYP1B1 and CYP3A4 gene polymorphisms in breast cancer patients.
Ociepa-Zawal M; Rubiś B; Filas V; Breborowicz J; Trzeciak WH
Ginekol Pol; 2009 Nov; 80(11):819-23. PubMed ID: 20088394
[TBL] [Abstract][Full Text] [Related]
8. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer.
Plummer SJ; Conti DV; Paris PL; Curran AP; Casey G; Witte JS
Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):928-32. PubMed ID: 14504207
[TBL] [Abstract][Full Text] [Related]
9. The CYP3A4 *1B polymorphism and prostate cancer susceptibility in a Portuguese population.
Nogal A; Coelho A; Catarino R; Morais A; Lobo F; Medeiros R
Cancer Genet Cytogenet; 2007 Sep; 177(2):149-52. PubMed ID: 17854673
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent.
Taioli E; Sears V; Watson A; Flores-Obando RE; Jackson MD; Ukoli FA; de Syllos Cólus IM; Fernandez P; McFarlane-Anderson N; Ostrander EA; Rodrigues IS; Stanford JL; Taylor JA; Tulloch-Reid M; Ragin CC
Prostate; 2013 May; 73(6):668-76. PubMed ID: 23129512
[TBL] [Abstract][Full Text] [Related]
11. CYP3A4*1B polymorphism and cancer risk: a HuGE review and meta-analysis.
Zhou LP; Yao F; Luan H; Wang YL; Dong XH; Zhou WW; Wang QH
Tumour Biol; 2013 Apr; 34(2):649-60. PubMed ID: 23179402
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.
Sarma AV; Dunn RL; Lange LA; Ray A; Wang Y; Lange EM; Cooney KA
Prostate; 2008 Feb; 68(3):296-305. PubMed ID: 18163429
[TBL] [Abstract][Full Text] [Related]
13. CYP3A4: a potential prostate cancer risk factor for high-risk groups.
Zeigler-Johnson C
Clin J Oncol Nurs; 2001; 5(4):153-4. PubMed ID: 12690615
[TBL] [Abstract][Full Text] [Related]
14. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
15. CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia.
Tayeb MT; Clark C; Haites NE; Sharp L; Murray GI; McLeod HL
Br J Cancer; 2003 Mar; 88(6):928-32. PubMed ID: 12644831
[TBL] [Abstract][Full Text] [Related]
16. CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification?
Kittles RA; Chen W; Panguluri RK; Ahaghotu C; Jackson A; Adebamowo CA; Griffin R; Williams T; Ukoli F; Adams-Campbell L; Kwagyan J; Isaacs W; Freeman V; Dunston GM
Hum Genet; 2002 Jun; 110(6):553-60. PubMed ID: 12107441
[TBL] [Abstract][Full Text] [Related]
17. Genetic association in
Bellah SF; Salam MA; Billah SMS; Karim MR
Ann Hum Biol; 2023 Feb; 50(1):63-74. PubMed ID: 36688864
[TBL] [Abstract][Full Text] [Related]
18. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.
Floyd MD; Gervasini G; Masica AL; Mayo G; George AL; Bhat K; Kim RB; Wilkinson GR
Pharmacogenetics; 2003 Oct; 13(10):595-606. PubMed ID: 14515058
[TBL] [Abstract][Full Text] [Related]
19. African American-preponderant single nucleotide polymorphisms (SNPs) and risk of breast cancer.
Kato I; Cichon M; Yee CL; Land S; Korczak JF
Cancer Epidemiol; 2009 Jul; 33(1):24-30. PubMed ID: 19679043
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms and prostate cancer risk.
Gsur A; Feik E; Madersbacher S
World J Urol; 2004 Feb; 21(6):414-23. PubMed ID: 14648103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
